Share Prices & Company Research

Market News

21 Aug 2018 | 08:36

Collagen Solutions pens distribution agreements with two new Chinese partners

Biomaterials and regenerative manufacturer Collagen Solutions said Tuesday it had signed distribution agreements with two new Chinese channel partners, Dakewe Biotech and Shanghai Regenic Biomedical.

The appointment of these channel partners followed the restructuring of the company's presence in China and the securing of export licences earlier this year.

Dakewe Biotech would distribute Collagen Solutions' products to the research market and engage in business to business sales to the medical device industry.

Shanghai Regenic Biomedical was recently established to sell and distribute collagen-based products to the medical device and regenerative medicine sectors.

Both distributors would bring different market access, qualities and advantages, and play a key role in the development of Collagen Solutions' sales and distribution channels within China, the company said. 'We have made good progress since our restructuring in China and the addition of these two new channel partners is testament to the growth opportunity for us there. We have been working hard to secure these distribution agreements and with these in place, we are now well positioned to engage further with customers in China,' said Jamal Rushdy, CEO of Collagen Solutions.

At 8:36am: (LON:COS) Collagen Solutions Plc share price was +0.1p at 3.75p

Story provided by StockMarketWire.com
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.